Otitis media with effusion in under 12s

The consultation closes on 12 May 2023 at 5pm

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline
• Evidence reviews:
• Evidence review A - modifiable risk factors for developing OME in children
• Evidence review B - presenting features associated with OME in children
• Evidence review C - natural history of OME without hearing loss
• Evidence review D - natural history of OME-related hearing loss
• Evidence review E – ventilation tubes
• Supporting evidence  – MacKeith 2023a (ventilation tubes)
• Evidence review F - adenoidectomy for children with otitis media with effusion (OME)
• Supporting evidence – MacKeith 2023b (adenoidectomy)
• Evidence review G – antibiotics
• Supporting evidence – Mulvaney 2023a (antibiotics)
• Evidence review H – non-antimicrobial pharmacological interventions for children with OME
• Supporting evidence – Mulvaney 2023b (steroids)
• Evidence review I - auto-inflation for children with otitis media with effusion (OME)
• Supporting evidence – Webster 2023 (autoinflation)
• Evidence review J - hearing aids/devices for hearing loss associated with OME in children under 12 years
• Evidence review K - preventing otorrhoea after surgery for hearing loss associated with OME in children
• Evidence review L - treating otorrhoea after surgery for hearing loss associated with OME in children
• Evidence review M - follow-up strategy after surgical treatment for OME-related hearing loss
• Evidence review N - information for suspected or confirmed OME
• Supporting documentation 1 – methods chapter
• Supporting documentation 2 – NICE Technical team list
• Supporting documentation 3 – Evidence from 2008 guideline
• Supporting documentation 4 – OME decision table
• Economic model
• Equality impact assessment 3

If you want to review the economic model (see Evidence review E, appendix I), please see 5. Economic models below and fill in the confidentiality form.

Other information about the consultation

• Committee member list
• Developing NICE guidelines: how to get involved
• Scope (for information only, not for commenting on)

3. Add your comments

• You must use this comments form.
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: Otitis@nice.org.uk

Deadline: 12 May 2023 at 5pm

5. Economic model

The developer has produced an economic model to support the guideline on Otitis media with effusion in under 12s. To receive an executable version of this model, please submit a request to otitis@nice.org.uk with a signed copy of the confidentiality acknowledgement and undertaking form.

We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: 12 May 2023 at 5pm.